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Background: Hyperlipidaemia is a major risk factor for coronary artery disease (CAD) and cholesteryl ester transfer
protein (CETP) gene polymorphisms are known to be associated with lipid profiles.
Methods: In this study, we investigated the association of two polymorphisms in the CETP, Taq1B (rs708272)
and -629C > A (rs1800775), with CAD and lipid levels HDL-C in 662 CAD + cases and 927 controls from the
Singapore population comprising Chinese, Malays and Indians.
Results: TaqB2 frequency was significantly lowest in the Malays (0.43) followed by Chinese (0.47) and highest in the
Indians (0.56) in the controls. The B2 allele frequency was significantly lower in the Chinese CAD + cases compared
to the controls (p = 0.002). The absence of the B2 allele was associated with CAD with an OR 2.0 (95% CI 1.2 to 3.4)
after adjustment for the confounding effects of age, smoking, BMI, gender, hypertension, dyslipidemia and diabetes
mellitus. The B2 allele was significantly associated with higher plasma HDL-C levels in the Chinese men after
adjusting for confounders. Associations with plasma apoA1 levels were significant only in the Chinese men for
Taq1B and -629C > A. In addition, the Taq1B polymorphism was only associated with plasma Apo B and Lp(a) in the
Malay men. Significant associations were only found in non-smoking subjects with BMI <50th percentile. In this
study, the LD coefficients between the Taq1B and -629C > A polymorphisms seemed to be weak.
Conclusion: The absence the Taq1B2 allele was associated with CAD in the Chinese population only and the minor
allele of the Taq1B polymorphism of the CETP gene was significantly associated with higher plasma HDL-C levels in
Chinese men.
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Coronary artery diseaseIntroduction
The inverse relationship between plasma high density
lipoprotein-cholesterol (HDL-C) and the incidence of
coronary artery disease (CAD) is well established [1,2].
HDL is thus believed to be a protective factor against
CAD. The removal of cholesterol from tissues and its de-
livery to the liver for excretion constitute the process of
reverse transport [3,4]. One of the important components* Correspondence: paehck@nus.edu.sg
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reproduction in any medium, provided the orof this process is the cholesteryl ester transfer protein
(CETP). CETP facilitates the transfer of cholesteryl ester
from HDL to triglyceride-rich lipoproteins in exchange for
triglycerides (TG) [5,6]. Many CETP DNA polymorphisms
that may alter the function of CETP have been reported
[7-9]. However, the association of these polymorphisms
with phenotypes such as lipid levels and the CAD remain
inconsistent [10-14].
Among the several CETP polymorphisms reported,
some are found to be associated with plasma levels of
HDL-C. One of the most widely studied polymorphic
sites on the CETP gene is the Taq1B site [15,16]. This is
a polymorphism at nucleotide 277 in intron 1(277C > T,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has been shown to be associated with elevated plasma
HDL-C levels in numerous studies [17-21]. It has been
reported that the Taq1B site is in linkage disequilibrium
(LD) with another polymorphic site (−629C >A, rs1800775)
in the CETP promoter region [22,23] and the latter could
explain the association between Taq1B and HDL-C levels
since it was shown to be a functional base substitution.
However, a subsequent study in the Icelandic population
reported that the -629C >A polymorphism does not explain
the association of Taq1B polymorphism with risk of myo-
cardial infarction although both are associated with HDL-C
levels [24].
The effects of CETP polymorphisms have been reported
in some of the Asian populations such as Sri Lankans [25],
Koreans [26],Taiwanese [27,28] Chinese [29], Indians
[30,31] and Turkish [32].The multi-ethnic Singaporean
population is also studied for the Taq1B and -629C >A
polymorphisms at the CETP locus for their association with
lipid levels [33]. However, the study was conducted in the
general population and hence the association of the poly-
morphisms with CAD could not be determined. On the
other hand it is noted that the mortality rate of CAD in the
ethnic Asian Indians is more than three times of the Chin-
ese [34]. The impact of the CETP genetic variants on com-
plex outcomes such as CAD is also warranted by
Thompson et al. [8]. As far as lipid profile is concerned the
plasma HDL-C level is shown to be one of the most dis-
criminative factors for CAD in Singapore population [35].
Singapore offers a good context for studying the gen-
etic effects on CAD and lipid levels as three major di-
verse ethnic groups are residing in this small island
state. We report here the allele frequencies and the asso-
ciation of the CETP Taq1B and -629C >A polymor-
phisms with CAD and lipid levels in the Chinese, Malays
and Asian Indians residing in Singapore.
Materials and methods
Ethics
This study was approved by the institutional ethics com-
mittee of National University of Singapore (NUS) IRB and
all subjects gave their informed consent for their participa-
tion in the study.
Study design
This was a case–control study. The cases were the an-
giographically confirmed CAD patients while the con-
trols were selected from the general population who
attended routine medical examination at a health screen-
ing centre as required by their employers.
Study subjects
A total of 662 angiographically confirmed CAD patients
(CAD+) who were admitted consecutively for coronaryartery by-pass graft at Singapore’s National Heart Centre
between 1995 and 2002 were included as cases in this
study. All patients had more than 50% stenosis in at
least one of the major coronary arteries as diagnosed by
angiography.
Separately, 927 consecutive individuals from the gen-
eral population, who attended routine medical examin-
ation at a community screening centre, without the
history of heart disorders and ECG abnormalities were
recruited as controls.
Sample collection and biochemical tests
The blood samples from the CAD + cases were collected
before their by-pass operation for routine examination in-
cluding lipid levels. The blood samples from the controls
were collected in tubes containing EDTA as anti-coagulant
after an overnight fast of at least 10 hours as a part of rou-
tine examinations and tests. The plasma was separated by
centrifugation and aliquot portions were stored at −20°C
until use. Measurement of plasma lipids and DNA extrac-
tion were carried out as previously described [36].
Genotyping
The Taq1B polymorphism was genotyped by restriction
fragment length polymorphism (RFLP) assay. A 535 bp
fragment in the intron 1 of the CETP gene was amplified
by using the primers 5' CACTAGCCCAGAGAGA
GGAGTGCC3' and 5' CTGAGCCCAGCCGCACACT
AAC3'. Amplification was carried out in a volume of 20
μl containing 1 - 10μg of genomic DNA, 20 pmol of
each primer, 0.5 mM of each dNTP, reaction buffer, 2%
DMSO and 1.0 U of Taq DNA polymerase. Amplified
products were digested overnight with 8 μl of Taq1 at
65 0C. The resulting fragments were 174 and 361 bp for
B1 allele and 535 bp for B2 allele.
Allele specific amplification was used to identify the -
629C >A promoter polymorphism. The common sense
primer was GGCAGCTTTGGTATTGGAG. The specific
anti-sense primers for the A and C allele were GATAT
GCATAAAATAACTCTGAGG and GATATGCATAAAA
TAACTCTGAGT respectively. We found that creating a
deliberate mismatch at the -627C nucleotide by changing
it to A in both primers could yield better allele discrimin-
ation. The amplicons were visualized by electrophoresis
on 2.5% agarose gel. The specific amplified fragment was
398 bp in length. Another pair of primers from ABCA1
gene was introduced into the system as an amplification
control: sense, CTTCACTCCCATATTTCAGAACTTG
and anti-sense, ATCTCCATTAAAGCATCCTACAGC.
The control product was 276 bp long.
Statistical analysis
The majority of statistical analysis was performed using
SPSS Version 19. The chi-squared (χ2) analysis was used
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(HWE) and for differences in allele frequencies between
groups. Analysis of covariance (ANCOVA) was per-
formed to determine the effects of the CETP gene poly-
morphisms on the various lipid traits using significant
confounding factors such as age, BMI and cigarette
smoking as covariates. The significance of the sample
variance was tested by F and P values while percentage
of explained variance (R2 x 100) was calculated from the
sum of squares. Due to their skewed distribution, the
raw data for TG and Lp(a) were normalized by natural
logarithm transformation prior to analysis. The LD be-
tween the Taq1B and -629C >A sites was indicated
by r2. Statistical significance was taken at α =0.05.
In the combined samples, the association analysis was
performed between plasma HDL-C levels and CETP gene
polymorphisms using linear model and was also assessed
for the homogeneity using Cochrane's Q statistic and I2
heterogeneity index in meta-analysis in PLINK.
Wherever appropriate, the analyses were performed
separately for men and women given the differences in
lipid levels that exist in these groups. The association be-
tween CETP polymorphism and lipid profile was evalu-
ated only in the control group because the lipid levels in
the CAD + cases may be influenced by the lipid loweringTable 1 Demographics of the study subjects in three ethnic p
Chinese
Variables Control CAD+ P Control
n = 383 n = 442 n =155
Age (years) 42.74 ± 14.2 59.34 ± 8.9 <0.0005 40.66 ± 9.24
BMI (kg/m2) 23 ± 3.61 24.24 ± 3.67 ns 25.17 ± 4.06
Smokers* (%) 17.4 52.9 <0.0005 52.7
Sex (%)
Female 46.1 21.9 <0.0005 8.7
Male 53.9 78.1 91.3
Dyslipidemia 46.3% 32.6% <0.0005 56.4%
Hypertension 8.2% 69.1% 4.1%
Diabetes Mellitus 2.7% 43.3% 3.4%
TC(mM) 5.81±1.19 4.57±1.14 <0.0005 5.85±1.22
HDL-C (mM) 1.4 ± 0.4 0.97 ± 0.26 <0.0005 1.19 ± 0.27
LDL-C (mM) 3.57 ± 1.17 2.78 ± 0.99 <0.0005 3.7 ± 1.23
TG (mM) 1.84 ± 1.9 1.37 ± 0.66 0.008 2.09 ± 1.31
ApoA1 (mg/dl) 144.4 ± 22.04 119.47 ± 20.5 <0.0005 129.29 ± 18.
ApoB (mg/dl) 106.2 ± 31.4 89.78 ± 22.6 <0.0005 121.36 ± 29
Lp(a) (mg/dl) 16.90 ± 22.67 24.33 ± 27.38 0.007 14.66 ± 15.1
Age, BMI and plasma lipid profiles are presented in mean ± SD. Continues and cate
test respectively.
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
Apolipoprotein; Lp(a), lipoprotein(a).
*Smokers and ex-smokers form one category while non-smokers constitute anotheragents that some of these patients had received follow-
ing the diagnosis of CAD.
Results
Subject characteristics
The subject characteristics of the study population for
three ethnic populations for CAD + and controls are
given in Table 1.
Significant differences between CAD + cases and con-
trols were observed for most components of the lipid
profiles. Among these, TC, LDL-C, TG and apolipopro-
tein (apo) B were significantly lower in the CAD + cases
as against the controls of all ethnic groups. Proportion
of subjects with Hypertension and diabetes was signifi-
cantly higher in CAD + cases as compared to control.
However, higher proportion of subjects was dislipedemic
in controls as compare to cases. These were expected as
most CAD + cases were on lipid-lowering drugs. Plasma
levels of Lp(a), which is very resistant to modification,
was significantly higher in the CAD + cases as against
the controls in all ethnic groups . As the mean age of
the CAD + cases was significantly higher than the con-
trols, we carried out logistic regression to determine if
age was significantly related to the allele frequencies of
both polymorphisms and found that it was not. We wereopulations
Malays Indians
CAD+ P Control CAD+ P
n = 110 n = 389 n = 110
59.08 ± 9.18 <0.0005 42.43 ± 14.08 60.35 ± 10.25 <0.0005
26.14 ± 3.62 ns 24.77 ± 4.8 24.9 ± 3.2 ns
49 ns 13.6 43.8 <0.0005
23.9 0.001 37.8 16.5 <0.0005
76.1 62.2 83.5
27.5% <0.0005 63.4% 21.1% <0.0005
72.7% 9.8% 61.8%
62.6% 6.4% 61.8%
4.6±1.13 <0.0005 5.61±1.22 4.25±1.99 <0.0005
0.91 ± 0.27 <0.0005 1.11 ± 0.32 0.88 ± 0.23 <0.0005
2.89 ± 1.03 <0.0005 3.62 ± 1.15 2.58 ± 0.86 <0.0005
1.51 ± 0.68 0.014 1.93 ± 1.45 1.29 ± 0.63 <0.0005
5 115.29 ± 20.8 <0.0005 135.85 ± 25.11 110.01 ± 19.8 <0.0005
103.64 ± 28 <0.0005 122.87 ± 33.04 102.3 ± 26.5 <0.0005
6 19.5 ± 16.28 0.032 21.9 ± 21.17 26.89 ± 11.4 0.038
gorical data were tested using independent sample t-test and Chi-square
lipoprotein cholesterol; TG, triglyceride; BMI, body mass index; Apo,
.
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lele frequencies between CAD + cases and controls were
not due to the confounding effects of age.
Frequency distribution of the polymorphisms
Figure 1 shows the genotype and allele distributions of
the two polymorphisms in the controls and CAD +
cases, among the three ethnic groups in Singapore.Figure 1 Genotype and allele frequencies of the TaqIB and -629C/A p
cases and controls. HWE χ2 : χ2 -test for departure from Hardy Weinberg
comparison between controls and CAD+ cases. P-values were obtained aft
hypertension, dyslipidemia and diabetes mellitus.Based on frequencies in the controls, the B2 allele fre-
quency was lowest in the Malays (0.43) followed by Chinese
(0.47) and highest in the Indians (0.56). The B2 frequency
was significantly lower in Malay controls as compared to
the Indians (p = 0.01) and Chinese (p = 0.005) controls. In
all ethnic groups, B1 was the major allele.
The -629C allele was predominant in Chinese (0.52)
and Malays (0.60) controls, but not in Indians (0.30).romoter polymorphisms in the three ethnic populations for CAD+
equilibrium. Pearson Chi-Square is the test statistic for allele frequency
er adjustment for gender, age, smoking status, body mass index,
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trols of all ethnic groups. The genotype distributions of
both polymorphisms in all three ethnic groups were
consistent with Hardy Weinberg expectations.
Case–control differences in allele frequencies
Apart from the highly significant lower B2 allele in
the Chinese CAD + cases compared to the controls
(p = 0.002), the allele frequencies for both the promoter and
Taq1B polymorphisms are not significantly different be-
tween CAD + cases and controls in all the ethnic groups.
The odds ratio for CAD associated with the absence of
B2 allele is 2.0 (95% CI 1.2 to 3.4) after adjustments were
made for the confounding effects of age, cigarette smok-
ing, BMI, gender, hypertension, dyslipidemia and dia-
betes mellitus by logistic regression. The absence of B2
allele is hence independently associated with CAD in the
Chinese but not for the Malays and Indians. There is no
significant association of the -629C >A polymorphism
with CAD.
LD between Taq1B and-629C > A sites
The LD coefficients between the Taq1B and -629C >A
polymorphisms are presented in Table 2. It is interesting
to note that LD is stronger in control than in cases for
the Chinese (0.38 vs. 0.10) and Malays (0.38 vs. 0.07),
but not for the Indians (0.11 vs. 0.12). With the max-
imum r2 value in controls being 0.388, considering the
cut off of 0.80 [37], there seems to be a weak LD be-
tween the two polymorphism studied.
Impact of CETP polymorphisms on plasma lipid profile
The association of the Taq1B and -629C >A polymor-
phisms with lipid levels in our population show ethnic
and gender-specificity (Tables 3 and 4). All analyses were
carried out with age, BMI, smoking status, hypertension
and diabetes mellitus as covariates. Consistent associ-
ation of the minor allele B2 with higher plasma HDL-C
levels in the Chinese men was observed in the Taq1B
polymorphism studied. Plasma HDL–C level was in the
order B1B1 < B1B2 < B2B2 (p = 0.004). Associations with
plasma apoA1 levels were significant only in the ChineseTable 2 Linkage disequilibrium coefficients between the
Taq1B and –629C/A sites in the three ethnic populations







Indians 0.128men for Taq1B (p < 0.001) and -629C >A (p = 0.029).
The other lipids that are significantly associated with the
polymorphisms are shown in Tables 3 and 4.
Since there are two polymorphisms on the same CETP
gene, we examined the combined effects of both poly-
morphisms on plasma lipid levels using their composite
genotypes. All 9 possible combinations of genotypes are
present in our population. However, two composite ge-
notypes, CC/B2B2 and AA/B1B1, were excluded from
the analysis because there was only one subject in the
former and two subjects in the latter although their
levels are still shown in Figure 2. Significant effects of
the composite genotypes on HDL-C and apoA1 in the
Chinese men are observed. ANCOVA results showed
that these are highest when both polymorphic sites are
homozygous for the minor alleles (Figure 2).
We also carried out two-way ANCOVA to assess the
effects of the two polymorphisms on HDL-C and apoA1
levels in the control group of Chinese men. When the
Taq1B polymorphism was included in the two-way
ANCOVA model with adjustment for the confounding
effects of age, BMI, smoking, hypertension and diabetes
mellitus, the -629C >A promoter site showed no signifi-
cant association with HDL-C and apoA1 (p = 0.455 and
0.812, respectively). However, in the presence of the pro-
moter genotypes, the Taq1B polymorphism remained
significantly associated with HDL-C and apoA-1 (p =
0.039 and 0.009 respectively) indicating that the effects
of the Taq1B polymorphism are independent and not
due to its weak LD with the promoter polymorphism.
Moreover, we performed a fixed effect meta-analysis
across all three populations (Q > 0.05 and I2 = 0.00). The
Taq1B polymorphism showed highly significant associ-
ation with plasma HDL-C in the combined population
(p = 5.502e-06). However, -629C > A had no association
with HDL-C (p = 0.0991).
Gene-environmental interaction
Since BMI was found to be a significant confounding
factor of HDL-C and apoA1 levels, we examined the
interaction of CETP genotypes with BMI. Figure 3A
shows that the protective effect of the B2 allele was only
apparent for Chinese men subjects having BMI lower
than the 50th percentile, beyond which, HDL-C levels
were no longer significantly different between genotypes.
This was confirmed by carrying out ANCOVA separately
for subjects below and above the 50th percentile.
The Taq1B polymorphism effect was only significant
(p = 0.007) for the lower 2 quartiles but not the upper
two (p = 0.302). The -629C >A promoter polymorphism
followed a similar trend in the Chinese men (Figure 3B).
Another environmental factor which interacted with the
Taq1B genotypes is cigarette smoking. We found signifi-
cant protective effect of the B2 allele only in non-smoking




n = 184 n = 138 n = 239
Variables B1B1 B1B2 B2B2 P B1B1 B1B2 B2B2 P B1B1 B1B2 B2B2 P
n = 50 n = 95 n = 39 R2x100 n = 46 n = 75 n = 17 R2x100 n = 54 n = 133 n=52 R2x100
TC(mM) 5.62±1.12 5.88±1.25 6.03±1.24 P = 0.351 5.94±1.09 5.74±1.22 6.57±1.52 P = 0.055 5.81±1.16 5.90±1.29 5.62±1.30 P = 0.537
1.14 3.908 0.51
LDL-C(mM) 4.04±0.93 4.13±1.07 4.33±1.21 P = 0.458 4.37±1.05 4.13±1.22 4.93±1.56 P = 0.051 4.19±1.22 4.32±1.28 4.11±1.32 P = 0.716
0.85 3.99 0.27
HDL-C(mM) 1.15±0.23 1.28±0.35 1.31±0.32 P = 0.004 1.16±0.31 1.16±0.24 1.23±0.20 P = 0.407 0.96±0.22 1.03±0.29 1.07±0.27 P = 0.101
5.06 0.099 1.924
lnTG 2.17±2.59 2.33±2.96 1.93±0.63 P = 0.847 2.03±1.30 2.31±1.38 2.06±0.99 P = 0.569 2.31±1.24 2.34±1.75 1.85±1.20 P = 0.145
0.169 0.756 1.613
TG (mM) 8.79 10.26 6.88 7.60 10.06 7.86 10.06 10.34 6.33
ApoA-1(mg/dl) 130.96±12.93 142.21±19.14 140.81±21.43 P < 0.001 125.65±20.87 127.93±16.78 130.79±13.39 P = 0.625 126.81±21.67 133.89±23.88 136.85±22.24 P = 0.109
7.057 0.665 1.863
ApoB(mg/dl) 105.91±26.25 113.99±29.63 118.42±27.44 P = 0.191 127.65±26.95 118.54±29.96 105.67±26.69 P = 0.025 130.61±32.71 130.66±32.95 124.02±33.58 P = 0.590
1.690 3.992 0.435
lnLp(a) 1.82±0.71 2.11±1.09 2.04±0.84 P = 0.423 2.16±0.96 2.38±0.78 1.61±0.86 P = 0.026 2.63±0.90 2.46±1.00 2.38±1.08 P = 0.467
1.052 9.029 0.683




n = 162 n = 12 n = 142
Variables B1B1 B1B2 B2B2 P B1B1 B1B2 B2B2 P B1B1 B1B2 B2B2 P
n = 45 n = 81 n = 36 R2x100 n = 5 n = 5 n = 2 R2x100 n = 37 n = 73 n = 32 R2x100
TC(mM) 6.06±1.10 5.51±0.97 5.56±1.25 P = 0.102 5.99±1.42 4.80±0.63 5.92±0.40 P = 0.260 5.23±1.13 5.23±1.15 5.53±1.17 P = 0.338
3.536 30.203 1.304
LDL-C(mM) 4.22±1.18 3.70±0.96 3.62±1.27 P = 0.052 4.36±1.39 3.21±0.54 4.17±0.27 P = 0.223 3.56±1.18 3.58±1.17 3.80±1.17 P = 0.524
3.132 29.203 0.765






















Table 3 Genotypic lipid levels (Mean ± SD) of the Taq1B polymorphism in the three ethnic populations for controls (Continued)
lnTG 1.41±0.74 1.41±0.84 1.25±0.75 P = 0.733 0.89±0.33 1.24±1.01 1.86±1.53 P = 0.203 1.54±1.13 1.55±1.32 1.20±0.62 P = 0.291
0.326 20.65 1.681
TG (mM) 4.11 4.11 3.50 2.43 3.44 6.42 4.67 4.71 3.31
ApoA-1(mg/dl) 147.24±20.68 150.59±25.73 152.88±21.93 P = 0.561 144.13±11.75 146.33±23.79 149.33±8.50 P = 0.541 136.50±23.30 139.35±26.63 150.97±28.83 P = 0.07
0.709 5.537 3.773
ApoB(mg/dl) 96.98±25.75 89.72±21.93 88.75±32.74 P = 0.476 99.80±26.75 95.40±10.45 109.00±2.83 P = 0.459 113.78±32.03 110.51±31.06 117.35±33.01 P = 0.596
0.900 14.32 0.57
lnLp(a) 2.30±1.19 2.43±1.03 2.65±1.06 P = 0.428 2.31±0.77 2.82±0.88 3.22±1.001 P = 0.422 2.66±0.82 2.76±0.92 2.82±1.02 P = 0.841
1.259 17.70 0.284

























n = 201 n = 138 n = 235
Variables CC CA AA P CC CA AA P CC CA AA P
n = 49 n = 106 n = 46 R2x100 n = 43 n = 74 n = 21 R2x100 n = 32 n = 122 n =81 R2x100
TC (mM) 5.58±1.13 5.88±1.22 6.08±1.28 P = 0.094 5.74±1.05 5.97±1.42 5.96±0.89 P = 0.809 5.69±0.99 5.96±1.29 5.63±1.21 P = 0.270
2.310 0.296 1.101
LDL-C(mM) 3.51±1.07 3.76±1.09 3.77±1.15 P = 0.370 3.68±0.95 3.76±1.46 3.74±1.05 P = 0.946 3.74±0.87 3.92±1.22 3.63±1.11 P = 0.354
1.000 0.083 0.872
HDL-C(mM) 1.21±0.26 1.25±0.32 1.35±0.33 P = 0.114 1.17±0.29 1.15±0.25 1.26±0.25 P = 0.433 1.02±0.37 0.99±0.24 1.07±0.27 P = 0.130
3.280 0.996 1.746
lnTG 0.53±0.48 0.57±0.45 0.63±0.45 P = 0.736 0.55±0.52 0.69±0.55 0.59±0.54 P = 0.614 0.54±0.58 0.72±0.48 0.55±0.55 P = 0.087
0.286 0.621 2.017
TG (mM) 1.70 1.77 1.88 - 1.73 1.99 1.80 - 1.72 2.05 1.73 -
ApoA-1(mg/dl) 133.57±14.17 141.81±18.48 140.89±22.03 P = 0.029 124.50±19.38 127.78±17.14 134.48±16.39 P = 0.114 133.94±28.71 129.91±22.68 135.95±22.59 P = 0.201
3.350 3.238 1.409
ApoB(mg/dl) 111.43±30.09 116.13±28.86 120.56±32.60 P = 0.522 123.71±25.82 124.21±33.83 121.86±22.88 P = 0.850 124.41±28.28 134.53±33.71 122.61±31.47 P = 0.117
0.581 0.206 1.809
lnLp(a) 2.06±1.00 2.14±0.97 1.77±0.95 P = 0.218 2.13±0.99 2.19±0.92 2.03±0.71 P = 0.608 2.73±0.87 2.46±1.12 2.50±1.05 P = 0.524
1.865 1.095 0.722




n = 173 n = 13 n = 145
Variables CC CA AA P CC CA AA P CC CA AA P
n = 44 n = 94 n = 35 R2x100 n = 6 n = 6 n = 1 R2x100 n = 26 n = 63 n = 56 R2x100
TC (mM) 5.83±1.01 5.75±1.18 5.51±1.05 P = 0.583 5.78±1.37 5.32±0.81 4.85±0.00 P = 0.665 5.32±1.25 5.16±1.03 5.42±1.21 P = 0.104
0.562 7.841 2.776
LDL-C(mM) 3.62±1.01 3.57±1.18 3.21±1.04 P = 0.267 3.80±1.54 3.40±0.44 2.66±0.00 P = 0.620 3.41±1.06 3.26±0.96 3.43±1.14 P = 0.199
1.432 9.112 2.048






















Table 4 Genotypic lipid levels (Mean ± SD) of the -629C/A promoter polymorphism in the three ethnic populations for controls (Continued)
lnTG 0.16±0.50 0.22±0.55 0.19±0.49 P = 0.709 0.05±0.60 0.11±0.57 -0.54±0.00 P = 0.604 0.20±0.69 0.18±0.50 0.26±0.48 P = 0.629
0.323 9.592 0.536
TG (mM) 1.17 1.25 1.21 1.05 1.12 0.58 1.22 1.20 1.30
ApoA-1(mg/dl) 151.86±23.78 150.69±24.82 148.72±21.16 P = 0.853 146.00±11.12 145.50±22.35 160.00±0.00 P = 0.230 134.44±28.66 139.32±24.63 147.57±27.20 P = 0.094
0.196 21.127 3.314
ApoB(mg/dl) 97.29±28.20 95.84±30.02 88.88±26.80 P = 0.520 100.33±23.96 102.50±10.05 85.00±0.00 P = 0.687 116.48±33.29 106.74±27.52 117.37±34.39 P=0.014
0.689 7.222 4.429
lnLp(a) 2.53±1.23 2.41±1.02 2.45±1.07 P = 0.882 2.77±1.01 2.97±1.06 2.48±0.00 P = 0.909 2.90±1.02 2.75±0.98 3.00±0.89 P = 0.590
0.185 2.362 1.325





















Figure 2 Mean plasma HDL-C levels of the Taq1B and -629C/A
composite genotypes in the control group of Chinese men.
Error bars denote 95% confidence limits.
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http://www.lipidworld.com/content/12/1/85Chinese men (Figure 3C). This was also confirmed by
ANCOVA performed separately for non-smokers (0.001)
and smokers (p = 0.943). One should not interpret from
this figure that B1B1 smokers have higher HDL-C levels
as the difference in HDL-C levels between the smokers
and non-smokers is not statistically significant. A similar
trend was also observed for the -629C >A polymorphism
(Figure 3D).
Discussion
In this study we genotyped three Asian ethnic popula-
tions in Singapore for two polymorphisms of the CETP
gene to determine their allele frequencies and associ-
ation with CAD and plasma lipid levels. The allele fre-
quencies of the Taq1B polymorphism showed marked
ethnic differences. The B1 allele is most common in the
Malays but is the minor allele in the Indians. The minor
B2 allele in the Chinese and Malays are close to most
Caucasian frequencies reported [38].The allele frequen-
cies of Taq1B polymorphism in Indians, Malays and
Chinese are consistent with the respective studies
conducted previously in Sri Lankans [25], Taiwanese
[27] and Singaporeans [33]. Similar to B1, the -629C al-
lele is also the most common in the Malays (0.60) but is
the minor allele in the Indians (0.30).
Among the three major ethnic groups in Singapore, the
Chinese is the only group that shows a significantly lower
frequency of the B2 allele in CAD + cases compared to
the controls. This finding is consistent with observation in
the Caucasians [11] and suggests the association of the B2
with some protective factors of CAD in Chinese popula-
tion. Chinese subjects without the B2 allele have 2.0 times
higher risk of CAD relative to those who have at least one
copy of the B2 allele. This is independent of the effects ofage, smoking, BMI, gender, hypertension, dyslipidemia
and diabetes mellitus. However, this effect is not observed
in the Malays and Indians. In the Taiwanese, the odds ratio
for CAD was slightly higher for the B1B1 than B2B2
group, but no significant difference in Taq1B allele distri-
bution was observed between the control and CAD
groups [27]. Padmaja et al. [31] demonstrated that CETP
B1B1 of Taq1B was significantly associated with increased
risk for CAD (OR 2.7; 95% CI 1.5-3.3) in the Indian popu-
lation. The B2 allele is unlikely to be a functional mutation
as its position in the intron is not known to affect RNA
splicing or serves any other regulatory purposes. As such,
any phenotype that it is associated has to be due to its LD
with another functional site that is either within the CETP
gene or its functionally related genes nearby, such as the
lecithin-cholesterol acetyl transferase gene. Dachet et al.
[22] first reported the strong LD between -629C >A and
Taq1B polymorphisms. Later many more alleles in the
CETP gene [39-41] were also reported to be in LD with the
Taq1B site. In the Singaporean population, weak LD be-
tween Taq1B and -629C >A was consistently observed in
all three ethnic groups, although to varying extent. It is
highest in the Malays, followed by Chinese and Indians.
Wu et al. [23] observed a LD between Taq1B and -629C >
A polymorphic sites in the Chinese population from China.
The effect of the Taq1B intronic polymorphism in this
study could not be generalized across ethnic groups and
genders. This is expected since the magnitude of its ef-
fects is dependent upon the strength of its LD with a
functional site. Among the lipid traits that we have stud-
ied, the B2 allele is most evidently associated with raised
levels of protective factors such as HDL-C and its asso-
ciated apoA1. This trend of association was consistent in
all ethnic groups and genders although statistical signifi-
cance was attained only in the Chinese men. Significant
association of the B2 allele with elevated HDL-C was also
reported for the Framingham population [11], Chinese
population [23], Iranian population [19,20] and Tunisian
population [9]. In their studies, the protective effects of
the B2 allele on the development of CAD were observed
in association with increased HDL-C and decreased CETP
activity. The association of the B2 allele with higher
plasma HDL-C and / or apoA1 has been consistently ob-
served in many other studies [15,24,27,28,33,42] as well.
However, Rahimi et al. [14] indicated that the CETPB1 al-
lele is associated with increased risk of CAD and type 2
diabetes mellitus independent of plasma HDL-C level in
the Iranian population.
In this study, we have shown that the association of
the Taq1B site with HDL-C and apoA1 levels remains
independent of the effects of the promoter -629C >A.
Both sites have similar effects on apoA1. We asked the
question of whether the -629C >A site is the functional
mutation while Taq1B was merely showing significant



































































Figure 3 Mean genotypic plasma HDL-C levels in the control group of Chinese men according to A) BMI quartiles and Taq1B
genotypes; B) BMI quartiles and -629C > A genotypes; C) Cigarette smoking and Taq1B genotypes; D) Cigarette smoking and -629C > A
genotypes.
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http://www.lipidworld.com/content/12/1/85association with plasma lipid levels as a result of LD. We
concluded that this may not be the case. Firstly, a func-
tional mutation is likely to have its effect observed
across all ethnic groups and genders. However, we ob-
served effects of the promoter polymorphism only in
Chinese men. Although we cannot be conclusive that
the -629C >A polymorphism is not a functional muta-
tion since other genes and environmental factors could
have masked its moderate effect, its ethnic-and gender-
specific effects nevertheless suggests the unlikelihood of
this being so. Secondly, the strength of association with
HDL-C and apoA1 levels was consistently higher for the
Taq1B site than the promoter site. This should not be
the case if the -629C >A site is functional and Taq1B
site its marker. Moreover, in the two-way ANCOVA,
there was no effect of the promoter polymorphism when
the Taq1B site was included in the model. We postulated
that there could be other functional sites within or near
the CETP gene that the Taq1B site is in stronger LD with
than the promoter site. Both Taq1B and -629C >A poly-
morphisms could possibly have independent effects on
HDL-C and apoA1 levels and hence they do not show sig-
nificant effects individually when they are included in thesame 2-way ANCOVA model. In the Turkish population,
it was found that CETP -629C >A polymorphism was not
associated with CAD [43]. As with any complex traits, the
genotypic effect is usually confounded by environmental
factors. In this study, we found significant gene-
environmental interaction of the Taq1B polymorphism
with BMI and smoking. The protective effect of the B2 al-
lele was only observed in subjects having BMI <23 and in
non-smokers. This is consistent with other studies that ex-
amined the confounding effects of BMI [21,28,38] and
smoking [15,25,38,44].
We concluded that, i) the absence of the B2 allele was
associated with CAD in the Chinese, ii) the minor alleles
of the two polymorphisms were significantly associated
with higher plasma HDL-C levels in the Chinese men
(B2), iii) the effects of the polymorphisms were signifi-
cant only in non-smoking subjects with BMI up to the
50th percentile, iv) The effect of the Taq1B polymorph-
ism is not entirely dependent on the -629C/A site but
that it could be in LD with some other functional sites.Competing interests
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